ArticleOral and maxillofacial surgery2025
Dual-drug-loaded carbopol gel for enhanced oral wound healing: a curcumin-ciprofloxacin-based therapeutic approach.
Article in Oral and maxillofacial surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Current and emerging biomaterials for targeted drug delivery in osteomyelitis management.Discover nano · 2026Review
- Textural Properties of CarbopolGels (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic oral wounds are prone to infection and delayed healing, necessitating therapeutic gels that combine antimicrobial and regenerative functions. PURPOSE: This study aimed to develop and evaluate a dual-drug-loaded oral wound gel (NDWG) incorporating curcumin and ciprofloxacin to assess its antimicrobial, anti-inflammatory, cytocompatibility, and wound healing potential. MATERIALS AND
methodsNDWG was formulated using 1% Carbopol 940 as a gel base. The antimicrobial efficacy was tested against S. aureus, E. coli, and K. pneumoniae. The anti-inflammatory activity was measured using an albumin denaturation assay. Degradation and drug release were studied for 28 and 7 days, respectively. Cytocompatibility was evaluated using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assays and scratch wound closure in human keratinocytes (HaCaT) cells. A preliminary in vivo evaluation was conducted using the Inflammation-Proliferation-Remodelling (IPR) scale in patients (n = 30) undergoing non-complicated tooth extraction.
resultsNDWG showed concentration-dependent antimicrobial inhibition, moderate anti-inflammatory activity (~ 60% inhibition at 100 µg/mL), ~ 98% degradation at 28 days, and ~ 95% ciprofloxacin release within 7 days. HaCaT cells maintained > 90% viability with enhanced migration in scratch assays (78-94% closure at 48 h). Clinically, 26 of the 30 patients achieved mucosal closure by day 14, and 90% demonstrated complete remodelling at 6 weeks.
conclusionNDWG demonstrated promising antimicrobial, anti-inflammatory, and regenerative activities in vitro and favorable preliminary clinical outcomes. However, the findings should be interpreted cautiously given the small in vivo sample size and short follow-up period. Larger, randomized studies are required to confirm their clinical efficacy.
Indexed as
Identifiers
41310239What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.